http://www.itpeducation.com en-us ITPeducation.com - The France Foundation ITPeducation.com is an educational curriculum incorporating a series of activities intended to reach targeted learners throughout 2008. This educational curriculum is designed to provide evidence-based clinical information on the diagnosis and management of patients with ITP to hematologists, oncologists, and other health care professionals. To achieve successful clinical outcomes in the care of patients with ITP, practitioners must keep abreast of the latest information and best practices for effective ITP management. Visit www.ITPeducation.com to apply for CME Credit. ITP is one of the most common forms of autoimmune disease affecting adults and children. It occurs with an incidence of approximately 5-10 per 100,000 persons per year among adults and approximately 4-5 per 100,000 per year in children. Visit www.itpeducation.com to apply for CME Credit. ITPeducation.com mpereira@francefoundation.com Copyright 2008 The France Foundation Sat, 12 Jul 2008 03:01:00 EDT Mon, 16 Nov 2009 02:00:00 EDT 60 ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_06.mp3 http://www.itpeducation.com/podcast/ITPeducation_06.mp3 What is the pathologic connection between thrombocytopenia and cancer? What is the evidence on the use of thrombopoietic agents in patients with cancer and thrombocytopenia? Does the danger of thromboembolism in patients with cancer influence the management of thrombocytopenia? Describe the latest clinical evidence on the use of therapies stimulating platelet production in other patient populations prone to thrombocytopenia, including chronic liver disease and cancer patients. CME - Peer-to-Peer Dialogue Mon, 16 Nov 2009 02:00:00 EDT 00:14:13 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_05.mp3 http://www.itpeducation.com/podcast/ITPeducation_05.mp3 What is the liver's role in platelet homeostasis and how is it affected by chronic liver disease? Are there special considerations for different types of chronic liver disease? What is the role of anti-platelet antibodies in thrombocytopenia associated with CLD? What is the evidence on the use of thrombopoietic agents in this patient population? Describe the latest clinical evidence on the use of therapies stimulating platelet production in other patient populations prone to thrombocytopenia, including chronic liver disease and cancer patients. CME - Peer-to-Peer Dialogue Mon, 16 Nov 2009 02:00:00 EDT 00:17:32 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_04.mp3 http://www.itpeducation.com/podcast/ITPeducation_04.mp3 What is the most critical information regarding efficacy and safety to share with patients during each phase of ITP management? What are the risk/benefit considerations of the new thrombopoietic agents? What are the positive and negative outcome predictors for splenectomy? Are there biomarkers that can help select the best patients for different therapies or predict outcomes? Discuss recent findings on patient-assessed quality of life measures in ITP and how these issues may affect risk/benefit analyses and therapeutic management decisions in these patients. CME - Peer-to-Peer Dialogue Thu, 22 Oct 2009 02:00:00 EDT 00:13:17 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_03.mp3 http://www.itpeducation.com/podcast/ITPeducation_03.mp3 What are the major QoL indicators for patients with ITP? Is there a validated QoL instrument for ITP and how should it be used in clinical practice? What is the clinical evidence that immune suppressive and thrombopoietic therapies improve these indicators? What is the clinical evidence that splenectomy improves these indicators? Discuss recent findings on patient-assessed quality of life measures in ITP and how these issues may affect risk/benefit analyses and therapeutic management decisions in these patients. CME - Peer-to-Peer Dialogue Tue, 22 Sep 2009 02:00:00 EDT 00:10:54 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_02.mp3 http://www.itpeducation.com/podcast/ITPeducation_02.mp3 What are the major approaches? How is success defined and what is the evidence for each approach? What are the thrombopoietic agents that were recently approved, and what should practitioners know about their efficacy and safety? Are there emerging approaches that offer other therapeutic avenues? Assess the benefits and risks of current and emerging pharmacotherapies for ITP including the latest clinical evidence on efficacy and safety of agents that stimulate platelet production. CME - Peer-to-Peer Dialogue Fri, 28 Aug 2009 02:00:00 EDT 00:11:48 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_01.mp3 http://www.itpeducation.com/podcast/ITPeducation_01.mp3 What are the clinical findings that lead to a diagnosis of ITP? What pathologic mechanisms underlie the disease? How is the adult disease different from ITP in children? Describe how understanding of the underlying pathophysiology of idiopathic thrombocytopenic purpura (ITP) has evolved in recent years and the implications for therapeutic strategies. CME - Peer-to-Peer Dialogue Fri, 31 Jul 2009 02:00:00 EDT 00:12:07 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_Management_03.mp3 http://www.itpeducation.com/podcast/ITPeducation_Management_03.mp3 What is the optimal strategy for monitoring ITP patients? Describe any patient assessment and educational tools (or resources) that can help track therapeutic progress and can help to improve compliance in patients with ITP. Discuss emerging therapies for ITP. CME - Peer-to-Peer Dialogue Tue, 09 Dec 2008 02:00:00 EDT 00:10:44 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_Management_02.mp3 http://www.itpeducation.com/podcast/ITPeducation_Management_02.mp3 What medications are currently available to treat ITP and which are in clinical evaluation? How efficacious are they and for which patients are they most appropriate? What are the safety concerns with each? Discuss the current medications used in the treatment of ITP. CME - Peer-to-Peer Dialogue Wed, 06 Nov 2008 02:00:00 EDT 00:25:39 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_Management_01.mp3 http://www.itpeducation.com/podcast/ITPeducation_Management_01.mp3 What is the role of splenectomy in managing ITP? How efficacious is the procedure, which patients should receive this treatment, and what are the safety concerns? Discuss the risk and benefits of splenectomy in the management of ITP. CME - Peer-to-Peer Dialogue Mon, 29 Sep 2008 01:00:00 EDT 00:11:35 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_Diagnosis_03.mp3 http://www.itpeducation.com/podcast/ITPeducation_Diagnosis_03.mp3 What are the critical tests for diagnosing ITP? Identify the causes for thrombocytopenia. CME - Peer-to-Peer Dialogue Thu, 04 Sep 2008 01:00:00 EDT 00:20:54 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_Diagnosis_02.mp3 http://www.itpeducation.com/podcast/ITPeducation_Diagnosis_02.mp3 Accurate recognition of ITP involves excluding other conditions and causes of thrombocytopenia. What are the most common causes of thrombocytopenia that must be considered? Describe the differential diagnosis of ITP. CME - Peer-to-Peer Dialogue Thu, 07 Jul 2008 01:00:00 EDT 00:10:03 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com ITPeducation.com http://www.itpeducation.com/podcast/ITPeducation_Diagnosis_01.mp3 http://www.itpeducation.com/podcast/ITPeducation_Diagnosis_01.mp3 What are the critical pathophysiological processes underlying ITP? Discuss the pathophysiological processes of ITP. CME - Peer-to-Peer Dialogue Wed, 11 Jun 2008 01:00:00 EDT 00:19:54 Clinical Update, ITP Trials, ITP education, CME Podcast, Idiopathic Thrombocytopenic Pupura, The France Foundation, ITPeducation.com